MyFinsight
Home
Blog
About
Contact
Download
Download image
Net proceeds from
the issuance of...
$706,388K
Proceeds from stock
option exercises
$36,845K
(2444.54%↑ Y/Y)
Proceeds from the
issuance of common stock...
$513K
(-17.66%↓ Y/Y)
Net cash provided by
financing activities
$743,511K
(353.37%↑ Y/Y)
Effect of exchange rate
changes on cash and cash...
$16K
(128.57%↑ Y/Y)
Canceled cashflow
$235K
Net increase in cash
and cash...
$363,308K
(345.71%↑ Y/Y)
Canceled cashflow
$380,219K
Payment of deferred
offering costs
$235K
(-39.43%↓ Y/Y)
Proceeds from maturities
of marketable...
$107,000K
(-32.10%↓ Y/Y)
Stock-based compensation
expense
$13,398K
(-14.26%↓ Y/Y)
Accrued interest, net of
interest received
-$1,173K
(-15.91%↓ Y/Y)
Accrued expenses and
other current...
$629K
(-85.18%↓ Y/Y)
Change in deferred
taxes and uncertain...
-$511K
(-2121.74%↓ Y/Y)
Amortization of operating
lease assets
$411K
(-28.77%↓ Y/Y)
Depreciation and
amortization expense
$90K
(-71.79%↓ Y/Y)
Net cash used in
investing activities
-$298,043K
(-2301.64%↓ Y/Y)
Net cash used in
operating activities
-$82,176K
(-17.37%↓ Y/Y)
Canceled cashflow
$107,000K
Canceled cashflow
$16,212K
Purchase of marketable
securities
$405,043K
(138.34%↑ Y/Y)
Net loss
-$96,207K
(-8.28%↓ Y/Y)
Prepaid expenses and
other current assets
$1,181K
(2612.77%↑ Y/Y)
Accounts payable
-$512K
(-39.51%↓ Y/Y)
Operating lease
liabilities
-$430K
(22.52%↑ Y/Y)
Net accretion on
marketable securities
-$58K
(97.22%↑ Y/Y)
Back
Back
Cash Flow
source: myfinsight.com
Terns Pharmaceuticals, Inc. (TERN)
Terns Pharmaceuticals, Inc. (TERN)